Table 1.
Clinicopathological characteristics of study cohort
| Total, n = 39 | EEC, n = 25 | NEEC, n = 14 | p | |
|---|---|---|---|---|
| Age (years)a | 68 (50–88) | 68 (50–85) | 74,5 (54–82) | 0.098 |
| BMI (kg/m2)a | 26.9 (20–51) | 27.5 (20–51) | 25.7 (22–37) | 0.289 |
| Follow-up (months)a | 34 (1–168) | 34 (1–88) | 30 (2–168) | 0.946 |
| Hypertensionb | 0.133 | |||
| Yes | 17 | 9 (36%) | 8 (62%) | |
| No | 21 | 16 (64%) | 5 (38%) | |
| Diabetes mellitusb | 0.825 | |||
| Yes | 8 (21%) | 5 (20%) | 3 (23%) | |
| No | 30 (79%) | 20 (80%) | 10 (77%) | |
| Tumor grade | ||||
| 1 | 4 (10%) | 4 (16%) | ||
| 2 | 16 (41%) | 16 (64%) | ||
| 3 | 19 (48%) | 5 (20%) | 14 (100%) | |
| Histology | ||||
| Endometrioid | 25 (64%) | 25 (64%) | ||
| Non-endometrioid | 14 (36%) | 14 (36%) | ||
| Serous | 2 (5%) | 2 (5%) | ||
| Clear cell | 2 (5%) | 2 (5%) | ||
| Mixed | 5 (13%) | 5 (13%) | ||
| Carcinosarcoma | 5 (13%) | 5 (13%) | ||
| FIGO stage | 0.009* | |||
| Early (I-II) | 22 (56%) | 18 (72%) | 4 (29%) | |
| Advanced (III-IV) | 17 (44%) | 7 (28%) | 10 (71%) | |
| Recurrencec | 0.041* | |||
| Yes | 13 (33%) | 6 (24%) | 7 (58%) | |
| No | 24 (62%) | 19 (76%) | 5 (42%) | |
| EC related death | 0.542 | |||
| Yes | 9 (23%) | 5 (20%) | 4 (29%) | |
| No | 30 (77%) | 20 (80%) | 10 (71%) | |
*significant result, a Median value (range) b data missing in one patient, c data missing in two patients